Quick Summary:
In an age where health technology is rapidly advancing, it is crucial to stay informed about key industry shifts. Our exclusive market research report on the Global Cardiac Resynchronization Therapy (CRT) Devices Market, which is projected to grow substantially by 2030, serves as the guide you need to navigate the complexities of this dynamic landscape with confidence and insight.
Covering diverse geographical regions including the U.S, China, Japan, Canada, and Germany, this report offers an in-depth examination of major competitors like Abbott Laboratories and Boston Scientific Corporation, along with 42 other leading organizations in the field. Additionally, we offer premium features such as online interactive peer-to-peer collaborative bespoke updates, access to digital archives, and complimentary updates for one year, ensuring that you're always up to date with the latest industry developments. With our report, empower your business with the knowledge to make informed decisions and propel your success in the Cardiac Resynchronization Therapy Devices Market.
Global Cardiac Resynchronization Therapy (CRT) Devices Market to Reach $9.8 Billion by 2030
The global market for Cardiac Resynchronization Therapy (CRT) Devices estimated at US$5.4 Billion in the year 2022, is projected to reach a revised size of US$9.8 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2022-2030. CRT-Defibrillator (CRT-D), one of the segments analyzed in the report, is projected to record 7.4% CAGR and reach US$7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the CRT-Pacemaker (CRT-P) segment is readjusted to a revised 8.4% CAGR for the next 8-year period.The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 7.3% CAGR
The Cardiac Resynchronization Therapy (CRT) Devices market in the U.S. is estimated at US$1.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.Select Competitors (Total 42 Featured) -
- Abbott Laboratories
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- LivaNova PLC
- Medtronic PLC
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Cardiac Resynchronization Therapy (CRT) Devices?
What is the growth rate of the Global Market for Cardiac Resynchronization Therapy (CRT) Devices?
What is the forecasted size of the Global Market for Cardiac Resynchronization Therapy (CRT) Devices?
Who are the key companies in the Global Market for Cardiac Resynchronization Therapy (CRT) Devices?
Report Attribute | Details |
---|---|
No. of Pages | 194 |
Published | November 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 5.4 Billion |
Forecasted Market Value ( USD | $ 9.8 Billion |
Compound Annual Growth Rate | 7.7% |
Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- LivaNova PLC
- Medtronic PLC